• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Say what? Com­pas­sion­ate use pro­gram? What com­pas­sion­ate use pro­gram?

9 years ago
Pharma

As­traZeneca records an­oth­er R&D set­back, trig­ger­ing a melt­down at Synair­gen

9 years ago
R&D

The promise of de­sign­er mi­crobes in­spires a $130M mega-round for Zymer­gen

9 years ago
R&D

Au­ris tries to re­bound from PhI­II fail­ure with new tri­al de­sign; Kymab ties the knot with Shang­hai-based EpimAb

9 years ago
News Briefing

Il­lu­mi­na shares tank af­ter se­quenc­ing gi­ant falls short on rev­enue

9 years ago
R&D

No­var­tis-backed Gami­da Cell grabs a break­through tro­phy for ex­per­i­men­tal cell treat­ment

9 years ago
R&D

Su­per­nus gets a (tem­po­rary) boost as AD­HD drug clears PhI­Ib hur­dle

9 years ago
R&D

Deaths, ac­cu­sa­tions of in­sid­er trad­ing and an ear­ly warn­ing from Boehringer stir Han­mi con­tro­ver­sy

9 years ago
R&D

GSK at­tempts to re­make it­self in Chi­na with lo­cal ties

9 years ago
R&D
China

#ES­MO16: Boehringer drug flops on OS end­point; Medi­vir re­or­ga­nizes, cuts staff

9 years ago
News Briefing

The Sarep­ta dilem­ma: Bioethics ex­pert Arthur Ca­plan says it’s time to re­think how to reg­u­late com­pas­sion

9 years ago
People
Pharma

Take­da adds a $790M dis­cov­ery deal to an on­go­ing R&D over­haul

9 years ago
R&D
Pharma

Helsinn sets up a bou­tique in­vest­ment fund with a rov­ing eye for on­col­o­gy up­starts

9 years ago
Financing

Mer­ck’s glo­ri­ous vic­to­ry in lung can­cer marks a Russ­ian win­ter for Bris­tol-My­ers

9 years ago
R&D

No­var­tis heads to the fin­ish line with CDK 4/6 block­buster con­tender ri­bo­ci­clib

9 years ago
R&D

Tesaro makes its case for a clean sweep with ni­ra­parib - and shares soar again

9 years ago
R&D

Kite touts 12-month re­mis­sion da­ta from tiny CAR-T study; Iron­wood ex­ec dies in bike ac­ci­dent

9 years ago
News Briefing

Thumbs Up/Thumbs Down: Ma­jor in­sur­er de­liv­ers a bad blow to Duchenne fam­i­lies

9 years ago
Bioregnum
Opinion

Clo­vis shares tank af­ter in­vestors size up the dis­ap­point­ing da­ta on ru­ca­parib

9 years ago
R&D

Up­dat­ed In­cyte com­bo da­ta for epaca­do­stat/Keytru­da look promis­ing

9 years ago
R&D

Lethal ex­per­i­men­tal can­cer drug from Han­mi, Boehringer killed three pa­tients — re­port

9 years ago
R&D

Pfiz­er plots a big move (but it's not go­ing very far)

9 years ago
Pharma

Medicxi launch­es a di­a­betes up­start with $11M; Ar­row­head part­ners on hep B; Im­munother­a­py start­up gains $12.2M round

9 years ago
News Briefing

Reuters probe spot­lights a con­flict of in­ter­est be­tween biotech in­vestor F-Prime and gi­ant Fi­deli­ty

9 years ago
Financing
First page Previous page 1152115311541155115611571158 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.